Overview

Bioequivalence Study of Brexpiprazole Orally Disintegrating Tablets (ODT) 2mg

Status:
Completed
Trial end date:
2019-06-18
Target enrollment:
Participant gender:
Summary
To investigate the bioequivalence of brexpiprazole ODT 2 mg and brexpiprazole conventional tablet 2 mg
Phase:
Phase 1
Details
Lead Sponsor:
Otsuka Pharmaceutical Co., Ltd.
Treatments:
Brexpiprazole